IL139285A0 - Peg-lhrh analog conjugates, their preparation and use - Google Patents

Peg-lhrh analog conjugates, their preparation and use

Info

Publication number
IL139285A0
IL139285A0 IL13928599A IL13928599A IL139285A0 IL 139285 A0 IL139285 A0 IL 139285A0 IL 13928599 A IL13928599 A IL 13928599A IL 13928599 A IL13928599 A IL 13928599A IL 139285 A0 IL139285 A0 IL 139285A0
Authority
IL
Israel
Prior art keywords
peg
lhrh analog
preparation
conjugates
analog conjugates
Prior art date
Application number
IL13928599A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL139285A0 publication Critical patent/IL139285A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL13928599A 1998-04-28 1999-04-28 Peg-lhrh analog conjugates, their preparation and use IL139285A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8334098P 1998-04-28 1998-04-28
PCT/US1999/009160 WO1999055376A1 (fr) 1998-04-28 1999-04-28 Conjugues d'analogues de peg-lhrh

Publications (1)

Publication Number Publication Date
IL139285A0 true IL139285A0 (en) 2001-11-25

Family

ID=22177691

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13928599A IL139285A0 (en) 1998-04-28 1999-04-28 Peg-lhrh analog conjugates, their preparation and use
IL139285A IL139285A (en) 1998-04-28 2000-10-26 Peg-lhrh analog conjugates, their preparation and use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL139285A IL139285A (en) 1998-04-28 2000-10-26 Peg-lhrh analog conjugates, their preparation and use

Country Status (12)

Country Link
US (2) US6433135B1 (fr)
EP (1) EP1075282B1 (fr)
JP (1) JP2002512982A (fr)
AT (2) ATE297762T1 (fr)
AU (1) AU760381B2 (fr)
CA (1) CA2330448A1 (fr)
DE (2) DE69925830T2 (fr)
DK (1) DK1075282T3 (fr)
ES (2) ES2309618T3 (fr)
IL (2) IL139285A0 (fr)
PT (1) PT1075282E (fr)
WO (1) WO1999055376A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2263795C (fr) * 1997-06-06 2008-02-19 Kyowa Hakko Kogyo Co., Ltd. Polypeptides chimiquement modifies
EP1124961B9 (fr) 1998-10-23 2010-07-21 Kirin-Amgen Inc. Composes thrombopoietiques
CN1338924A (zh) 1999-01-08 2002-03-06 艾米斯菲尔技术有限公司 聚合物输送剂和输送剂化合物
JP4027663B2 (ja) * 1999-10-04 2007-12-26 ネクター セラピューティックス エイエル，コーポレイション ポリマー安定化神経ペプチド
UY26929A1 (es) * 2000-09-29 2002-04-26 Abbott Lab Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
ATE435035T1 (de) 2003-01-13 2009-07-15 Bracco Imaging Spa Verbesserte linker für radiopharmazeutische verbindungen
KR20060003862A (ko) 2003-03-14 2006-01-11 네오스 테크놀로지스, 인크. 수용성분기폴리머 및 그 접합체
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers
EP2263684A1 (fr) 2003-10-10 2010-12-22 Novo Nordisk A/S Dérives de IL-21
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
BRPI0506741A (pt) 2004-01-08 2007-05-15 Neose Technologies Inc glicosilação de peptìdeos ligados a o
CA2572765C (fr) * 2004-07-08 2013-05-21 Amgen Inc. Peptides therapeutiques
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
BRPI0519430A2 (pt) * 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
EP1858543B1 (fr) 2005-01-10 2013-11-27 BioGeneriX AG Facteur de stimulation de colonie de granulocytes glycopegylé
EP1857462B9 (fr) * 2005-02-18 2013-02-13 Nof Corporation Derive de polyoxyalkylene
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
EP2054521A4 (fr) 2006-10-03 2012-12-19 Novo Nordisk As Méthodes de purification de conjugués de polypeptides
RS52845B (en) 2007-04-03 2013-12-31 Biogenerix Ag TREATMENT PROCEDURES USING GLYCOPEGILATED G-CSF
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US20090149673A1 (en) * 2007-12-05 2009-06-11 Semprus Biosciences Corp. Synthetic non-fouling amino acids
EP2257311B1 (fr) 2008-02-27 2014-04-16 Novo Nordisk A/S Molécules de facteur viii conjuguées
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
US8383093B1 (en) 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
JP6290193B2 (ja) 2012-06-04 2018-03-07 オプコ バイオロジクス リミテッド ペグ化ｏｘｍ変異体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935491A (en) 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
JPH03148298A (ja) * 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
WO1994004193A1 (fr) * 1992-08-21 1994-03-03 Enzon, Inc. Nouvelle fixation d'oxydes de polyalkylene a des substances presentant une efficacite biologique
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7953788B2 (en) * 2001-09-29 2011-05-31 Siebel Systems, Inc. System and method for queuing data for an application server

Also Published As

Publication number Publication date
IL139285A (en) 2007-03-08
ES2242396T3 (es) 2005-11-01
DK1075282T3 (da) 2005-10-10
US20050222214A1 (en) 2005-10-06
AU3869699A (en) 1999-11-16
EP1075282B1 (fr) 2005-06-15
US6433135B1 (en) 2002-08-13
WO1999055376A1 (fr) 1999-11-04
US7268210B2 (en) 2007-09-11
ES2309618T3 (es) 2008-12-16
DE69939036D1 (de) 2008-08-14
EP1075282A1 (fr) 2001-02-14
PT1075282E (pt) 2005-09-30
DE69925830T2 (de) 2006-05-04
JP2002512982A (ja) 2002-05-08
CA2330448A1 (fr) 1999-11-04
ATE297762T1 (de) 2005-07-15
AU760381B2 (en) 2003-05-15
ATE399567T1 (de) 2008-07-15
DE69925830D1 (de) 2005-07-21

Similar Documents

Publication Publication Date Title
IL139285A0 (en) Peg-lhrh analog conjugates, their preparation and use
IL112372A0 (en) Non-viral vector
HUP0100507A2 (hu) Polietilén-glikol-GRF konjugátumok, eljárás azok helyspecifikus előállítására, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
UA66857C2 (uk) КОН'ЮГАТ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН, СПОСІБ ОДЕРЖАННЯ КОН'ЮГАТУ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН ТА СПОСІБ ЛІКУВАННЯ ІНФЕКЦІЙНИХ ХВОРОБ, ПУХЛИН І АУТОІМУННИХ І ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
WO1997044063A3 (fr) Conjugues d'acide cis-docosahexanoïque et d'agents pharmaceutiques
WO2003022210A3 (fr) Compositions pharmaceutiques de conjugues medicament-oligomere et methodes therapeutiques associees
NZ534618A (en) The preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
MX9700552A (es) Conjugados de vitamina b12 y proteinas.
ES2194114T3 (es) Formulaciones liposomicas de mitoxantrona.
DE69835201D1 (en) Neoglycoproteine
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
AP2001002187A0 (en) Piperidines as CCR5 modulators.
WO1997029779A3 (fr) Conjugues de egf-genisteine pour le traitement du cancer
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
MY119090A (en) Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
BG105275A (en) Tan-1057 derivatives
IL118218A (en) Pharmaceutical compositions containing sarcodictyins
EP0924219A3 (fr) Nouveaux estrènes exertant une action sur l'hypothalamus
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees